Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 10/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | TNNI3K | Q59H18 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ERBB3 | P21860 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1285052 | 0.77 | NPC1 (0.55) | NPC1EGFRMKNK1MEN1KMT2A | |
| SCHEMBL28805101 | 0.77 | NPC1 (0.69) | NPC1EGFRMKNK1TNNI3KMEN1 | |
| SCHEMBL5025314 | 0.77 | NPC1 (0.64) | NPC1EGFRMKNK1MEN1KMT2A | |
| SCHEMBL2279629 | 0.76 | EGFR (0.59) | NPC1EGFRMKNK1TNNI3KERBB3 | |
| SCHEMBL691533 | 0.76 | EGFR (0.57) | NPC1EGFRTNNI3KERBB3 | |
| SCHEMBL12517775 | 0.75 | NPC1 (0.43) | NPC1EGFRFGFR1MKNK1KDR | |
| SCHEMBL1285874 | 0.74 | NPC1 (0.53) | NPC1EGFRFGFR1MKNK1MEN1 | |
| SCHEMBL16205250 | 0.74 | MEN1 (0.49) | NPC1KDRTNNI3KMEN1KMT2A | |
| SCHEMBL14322256 | 0.73 | RAPGEF4 (0.46) | MEN1KMT2A | |
| SCHEMBL857502 | 0.69 | NPC1 (0.63) | NPC1EGFRMKNK1TNNI3KMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120329784-A1 | COMPOUNDS AND METHODS | GLAXOSMITHKLINE LLC | 2012-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329784-A1 | COMPOUNDS AND METHODS | RB1, DHFR, NQO1 | NPC1 383/4885EGFR 888/4885FGFR1 1844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.